UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                                     of the
                         SECURITIES EXCHANGE ACT OF 1934
                Date of Report (Date of earliest event reported):
                      November 17, 2006 (November 15, 2006)

                     CHINA BIOPHARMACEUTICALS HOLDINGS, INC.
                         ------------------------------
             (Exact name of registrant as specified in its charter)



       Delaware                          814-00063               13-2949462
(State or other jurisdiction     (Commission File Number)      (IRS Employer
      of incorporation)                                      Identification No.)

                           Suite 602, China Life Tower
                             No. 16, Chaowai Street
                           Chaoyang District, Beijing
                                      China
                           --------------------------
                    (Address of principal executive offices)

                                (86) 10 8525 1616
                      -------------------------------------
              (Registrant's telephone number, including area code)

       -------------------------------------------------------------------
          (former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))






ITEM 8.01. OTHER EVENTS

The  Company  issued a press  release  on the third  quarter  results  for 2006.
Attached is the press release discussing the results.



ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.


(d)      Exhibits.

         99.1.    Press release issued by the registrant on November 15, 2006.
























                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                         China Biopharmaceuticals Holdings, Inc.

                                         By:  /s/ Chris Peng Mao
                                            -----------------------------
                                            Name:  Chris Peng Mao
                                            Title: Chief Executive Officer

Dated:  November 17, 2006